Statins for secondary prevention of cardiovascular disease: The right dose

Pharmacology

Volumn 87, Issue 1-2, 2011, Pages 63-69

  Spector, Reynold ^a   Snapinn, Steven M ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b AMGEN INC   (United States)

Author keywords

Cholesterol; Coronary artery disease; Cost effectiveness; Dose response studies; Medication compliance; Simvastatin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HUMAN; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SINGLE DRUG DOSE; STROKE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL;

EID: 78651229602     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322999     Document Type: Review

References (28)

1. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. The LIPID Study Group: Long-term effectiveness and safety of pravastatin in 9,014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379-1387.
3. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals; a randomised placebo- controlled trial. Lancet 2002; 360: 7-22.
4. Sacks FM, Tonkin AM, Shepherd J, et al: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation 2000; 102: 1893-1900.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
6. Grundy SM, Cleeman JI, Merz CNB, et al: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004; 110: 227-239. (Pubitemid 38924592)
7. Shepherd J: Resource management in prevention of coronary heart disease: optimizing prescription of lipid-lowering drugs. Lancet 2002; 359: 2271-2273. (Pubitemid 34717986)
8. Donner-Banzhoff N, Sönnichsen A: Strategies for prescribing statins. Evidence supports prescribing a standard dose without further testing or dose adjustment. BMJ 2008; 336: 288-289.
9. Hayward RA, Hofer TP, Vijan S: Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006; 145: 520-530. (Pubitemid 46780956)
10. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S: Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med 2010; 152: 69-77.
11. Spector R: The Scientific Basis of Clinical Pharmacology: Principles and Examples. Boston, Little, Brown and Co, 1986.
12. LaRosa JC, Grundy SM, Waters DD, et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435. (Pubitemid 40471450)
13. Pedersen TR, Faergeman O, Kastelein JJP, et al: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA 2005; 294: 2437-2445. (Pubitemid 41627921)
14. SEARCH Study Collaborative Group Oxford: Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12,064 myocardial infarction survivors. Am Heart J 2007; 154: 815-823.
15. SEARCH Collaborative Group: Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a doubleblind randomized trial. Lancet 2010; 376: 1658-1669.
16. Boden WE, O'Rourke RA, Teo KK, et al: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516. (Pubitemid 46588415)
17. Tonino PA, De Bruyne B, Pijls NH, et al: Fractional flow reserve versus angiograph for guiding percutaneous coronary intervention. N Engl J Med 2009; 360: 213-224.
18. Mahmarian JJ, Dakik HA, Filipchuk NG, et al: An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol 2006; 48: 2458-2467. (Pubitemid 44881230)
19. Freund JE: Modern Elementary Statistics, ed 3. Englewood Cliffs, Prentice-Hall, 1967, pp 285-287.
20. Kulinskaya E, Morgenthaler S, Staudte RG: Meta-Analysis: A Guide to Calibrating and Combining Statistical Evidence. Chichester, Wiley, 2008.
21. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into metaanalysis. Trials 2007; 8: 16.
22. 2010. Atorvastatin. Montvale, PDR Network, 2010, pp 2504-2507.
23. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.
24. The SEARCH Study Collaborative Group: SLC 0131 variants and statin-induced myopathy - A genome wide study. N Engl J Med 2008; 359: 789-799.
25. Bates TR, Connaughton VM, Watts GF: Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009; 10: 2973-2985.
26. Shroufi A, Powles JW: Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health 2010; 64: 109-113.
27. Sackett DL, Haynes RB: Compliance with Therapeutic Regimens. Baltimore, Johns Hopkins University Press, 1976.
28. Cannon CP: The IDEAL cholesterol: lower the better. JAMA 2005; 294: 2492-2494.